Vimarsana
Biggest News Aggregation in the World

Page 8 - Injection System News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Injection System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Injection System Today - Breaking & Trending Today

SII to acquire 20 per cent stake in IntegriMedical - Vimarsana News

SII to acquire 20 per cent stake in IntegriMedical

Vaccines manufacturer Serum Institute of India (SII) on Friday said it is acquiring 20 per cent stake in IntegriMedical, to advance needle-free injection system technology. IntegriMedical has developed a US patented needle-free Injection System (N-FIS) that utilises high-velocity jet stream using

SII to acquire 20% stake in IntegriMedical - Vimarsana News

SII to acquire 20% stake in IntegriMedical

IntegriMedical has developed a US patented needle-free Injection System (N-FIS) that utilises high-velocity jet stream using mechanical power to effectively and consistently administer biologics and drugs, Serum Institute of India (SII) said in a statement.

FDA approves Bayer's Ultravist (iopromide) Injection for Contrast-enhanced Mammography - Vimarsana News

FDA approves Bayer's Ultravist (iopromide) Injection for Contrast-enhanced Mammography

Contrast-enhanced mammography (CEM) is an emerging modality combining digital mammography with the administration of a contrast agent 

FDA approves Bayer's Ultravist® (iopromide) injection for contrast-enhanced mammography | Business - Vimarsana News

FDA approves Bayer's Ultravist® (iopromide) injection for contrast-enhanced mammography | Business

WHIPPANY, N.J.--(BUSINESS WIRE)--Jun 23, 2023--

FDA approves Bayer's Ultravist® (iopromide) injection for contrast-enhanced mammography | Region - Vimarsana News

FDA approves Bayer's Ultravist® (iopromide) injection for contrast-enhanced mammography | Region

WHIPPANY, N.J.--(BUSINESS WIRE)--Jun 23, 2023--